Some clinicians prefer aspirin when balancing bleeding risk with the indication for an anticoagulant, Barnes said, reasoning ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Researchers have found in a cohort study that patients with atrial fibrillation (AF) receiving a factor Xa inhibitor and ...

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...

Heart disease is the leading cause of death in the U.S., a balanced diet and exercise can help you live a healthy life.

Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for ...

Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, ...

Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...